DeCure for Leukoencephalopathy with vanishing white matter 4
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for leukoencephalopathy with vanishing white matter 4 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLeukoencephalopathy with vanishing white matter 4 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for leukoencephalopathy with vanishing white matter 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
eukaryotic translation initiation factor 2B subunit delta (EIF2B4) — EIF2B4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9Y4B · 2.1 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The five autopsied patients who died of treatment-induced leukoencephalopathy after primary CNS lymphoma had a median age of 74 years at diagnosis. Symptoms of neurotoxicity began a median of one month after treatment finished, and median survival after neurotoxicity onset was 30 months. All had white matter hyperintensity on T2-weighted MRI; two developed enhancing lesions 5 and 14 months after treatment. At autopsy no lymphoma was found. All had myelin and axonal loss, gliosis, pallor, spongiosis, and rarefaction of the white matter; two had tissue necrosis matching the enhancing MRI lesions, and one had fibrinoid necrosis of vessels. Four of five had atherosclerosis of large cerebral vessels and all had small vessel disease; two had recent strokes at autopsy. The authors concluded that this leukoencephalopathy is not a late delayed effect but can appear very early, and that vascular disease may be part of the injury.
In vanishing white matter disease, which is an inherited disorder with chronic progression and episodes of rapid deterioration typically provoked by febrile infections or minor head trauma, two patients experienced such an episode after a fright. A 2010 review noted that understanding of leukodystrophies with late onset is increasing, with metabolic dysfunctions in peroxisomal lipid metabolism or energy homeostasis now thought to influence axonal integrity and oligodendrocyte function, leading to demyelination. That review also stated that many leukodystrophies are important to recognise because specific treatments already exist or are under investigation.
Toxic leukoencephalopathy from various toxins produces white matter signal abnormalities with or without restricted diffusion on MRI. These changes are often reversible if the offending agent is removed early, except in posthypoxic leukoencephalopathy, which can appear 1–2 weeks after the initial insult. The 2017 pictorial essay emphasised that many other causes of white matter signal abnormalities can mimic toxic leukoencephalopathy, so familiarity with causes, clinical presentation, and imaging is critical for early treatment and improved prognosis.
What is still missing is any trial of a specific drug for leukoencephalopathy with vanishing white matter 4; the abstracts provide no treatment data for that genetic subtype. No patient stratification by genotype, no prospective study design, and no funding for a dedicated clinical trial are reported. The 2010 review mentions existing or investigational treatments for some leukodystrophies but does not name them for this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2004 · 177 citations
Treatment-induced leukoencephalopathy in primary CNS lymphoma
AbstractBACKGROUND: Treatment-related leukoencephalopathy is the leading toxicity after successful treatment of primary CNS lymphoma (PCNSL). Its mechanism is poorly understood and there are no autopsy data available on such patients. METHODS: From a database of immunocompetent patients with PCNSL diagnosed between 1985 and 2001, the authors identified five autopsied patients who died of leukoencephalopathy. The authors reviewed their clinical records, MRI, and autopsy findings. RESULTS: The median age was 74 years (range 41 to 79) at PCNSL diagnosis. Symptoms of neurotoxicity developed a median of 1 month after treatment completion, and median survival was 30 months (range 22 to 68 months) after neurotoxicity onset. All had white matter hyperintensity on T2-weighted MRI, and two developed enhancing lesions 5 and 14 months following completion of treatment. At autopsy no PCNSL was identified. Myelin and axonal loss, gliosis, pallor, spongiosis, and rarefaction of the white matter were found in all; two patients had tissue necrosis that correlated with the enhancement on MRI, and one had fibrinoid necrosis of vessels. Four of the five patients had atherosclerosis of large cerebral vessels in the circle of Willis and all had small vessel disease; two had recent strokes at autopsy. CONCLUSIONS: Treatment-induced leukoencephalopathy is not a late delayed consequence of neurotoxic treatment but can be seen very early in some patients. Vascular disease may be a component of this white matter injury.
Fright is a provoking factor in vanishing white matter disease
AbstractLeukoencephalopathy with vanishing white matter is an inherited disorder with a chronic progressive disease course and additional episodes of rapid neurological deterioration. These episodes typically are provoked by febrile infections or minor head trauma. We report on two patients who experienced an episode of rapid neurological deterioration after a fright.
Current Opinion in Neurology · 2010 · 55 citations
Leukodystrophies with late disease onset: an update
AbstractPURPOSE OF REVIEW: Knowledge of the metabolic and genetic basis of known and previously unknown leukodystrophies is constantly increasing, opening new treatment options such as enzyme replacement or cell-based therapies. This brief review highlights some recent work, particularly emphasizing results from studies in adulthood leukodystrophies. RECENT FINDINGS: Evidence from recent studies suggests increasing importance of metabolic dysfunctions, for example, in peroxisomal lipid metabolism or energy homeostasis, influencing axonal integrity and oligodendrocyte function and leading to white matter demyelination. In addition, diagnostic and therapeutic progress in metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Krabbe diseases and other rare leukodystrophies with late onset are summarized. SUMMARY: Better understanding of leukodystrophies in neurological routine practice is of crucial importance for differentiating between other white matter diseases such as toxic, inflammatory or vascular leukoencephalopathies. Many leukodystrophies are particularly important to recognize because specific treatments already exist or are currently under investigation. The article also provides an overview of currently known leukodystrophies in adulthood.
Polish Journal of Radiology · 2017 · 27 citations · open access
Toxins in Brain! Magnetic Resonance (MR) Imaging of Toxic Leukoencephalopathy – A Pictorial Essay
AbstractToxic leukoencephalopathy results from damage to the white matter caused by various toxins. It manifests itself as white matter signal abnormalities with or without the presence of restricted diffusion. These changes are often reversible if the insulting agent is removed early, with the exception of posthypoxic leukoencephalopathy that can manifest itself 1-2 weeks after the initial insult. However, many other potential causes of white matter signal abnormalities can mimic the changes of toxic leukoencephalopathy. Thus, familiarity with the causes, clinical presentation and particularly imaging findings of toxic leukoencephalopathy is critical for early treatment and improved prognosis. The purpose of this pictorial essay is to familiarize the reader with the various causes of toxic leukoencephalopathy along with its differential diagnoses and mimics.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
